- Home
- STRW vs ELTX Comparison
STRW vs ELTX Comparison
Compare STRW & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- ELTX
- Stock Information
- Founded
- STRW 2015
- ELTX 2011
- Country
- STRW United States
- ELTX United States
- Employees
- STRW N/A
- ELTX N/A
- Industry
- STRW Real Estate Investment Trusts
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- STRW Real Estate
- ELTX Health Care
- Exchange
- STRW Nasdaq
- ELTX Nasdaq
- Market Cap
- STRW 151.1M
- ELTX 158.5M
- IPO Year
- STRW N/A
- ELTX N/A
- Fundamental
- Price
- STRW $12.03
- ELTX $8.77
- Analyst Decision
- STRW Strong Buy
- ELTX Strong Buy
- Analyst Count
- STRW 4
- ELTX 1
- Target Price
- STRW $12.72
- ELTX $13.00
- AVG Volume (30 Days)
- STRW 27.7K
- ELTX 104.1K
- Earning Date
- STRW 11-06-2025
- ELTX 11-13-2025
- Dividend Yield
- STRW 5.32%
- ELTX N/A
- EPS Growth
- STRW 19.41
- ELTX N/A
- EPS
- STRW 0.61
- ELTX N/A
- Revenue
- STRW $145,392,000.00
- ELTX N/A
- Revenue This Year
- STRW $33.39
- ELTX N/A
- Revenue Next Year
- STRW $5.21
- ELTX N/A
- P/E Ratio
- STRW $19.80
- ELTX N/A
- Revenue Growth
- STRW 29.76
- ELTX N/A
- 52 Week Low
- STRW $8.70
- ELTX $4.60
- 52 Week High
- STRW $12.84
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- STRW 55.90
- ELTX 34.58
- Support Level
- STRW $11.53
- ELTX $8.60
- Resistance Level
- STRW $12.28
- ELTX $9.49
- Average True Range (ATR)
- STRW 0.33
- ELTX 0.49
- MACD
- STRW 0.08
- ELTX 0.02
- Stochastic Oscillator
- STRW 78.45
- ELTX 14.10
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.